Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 5Gastrointestinal 3Other hematologic neoplasm 2CNS 2Lymphoid 1Dermatologic 1Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × peginterferon alfa-2a × Breast × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡